EWTX
Edgewise Therapeutics, Inc.Company Information
- Company Name
- Edgewise Therapeutics, Inc.
- CIK
- CIK0001710072
- Category
- Large accelerated filer
- Ticker: Exchange
- EWTX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- EWTX
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-11-11
- Last sale
- 2026-08-13
- Shares purchased (TTM)
- 10,700
- Shares sold (TTM)
- 668,736
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 118,543,411
- Shares outstanding
- 107,669,774
- Ownership
- 110.10%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -3.74%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 72 | 33 | 61 | 46 | 43 | 50 | 42 | 45 | 43 | 30 | 86 | 33 | ||||||
| Marketable Securities | 388 | 466 | 469 | 517 | 551 | 386 | 429 | 448 | 468 | 502 | 232 | 257 | ||||||
| Prepaid Expense And Other Assets Current | 6 | 10 | 13 | 11 | 9 | 7 | 5 | 7 | 8 | 9 | 9 | 8 | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | 4 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Assets Current | 472 | 510 | 543 | 574 | 603 | 443 | 475 | 499 | 519 | 541 | 327 | 298 | ||||||
| Property Plant And Equipment Net | 7 | 7 | 8 | 8 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 11 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Other Assets Noncurrent | - | - | - | - | - | 1 | 0 | 0 | 0 | - | 0 | 0 | ||||||
| Assets | 480 | 519 | 553 | 583 | 613 | 454 | 487 | 511 | 532 | 554 | 340 | 311 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 5 | 7 | 6 | 6 | 8 | 9 | 6 | 6 | 7 | 5 | 4 | 5 | ||||||
| Employee Related Liabilities Current | 9 | 6 | 12 | 8 | 6 | 4 | 10 | 6 | 4 | 3 | 6 | 4 | ||||||
| Accrued Liabilities Current | 5 | 9 | 8 | 6 | 6 | 7 | 7 | 6 | 5 | 6 | 6 | 6 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | 10 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities Current | 29 | 23 | 27 | 22 | 21 | 21 | 24 | 19 | 17 | 15 | 17 | 16 | ||||||
| Operating Lease Liability Noncurrent | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 3 | 4 | 4 | 4 | 5 | ||||||
| Liabilities | 32 | 25 | 30 | 25 | 24 | 25 | 28 | 22 | 21 | 19 | 21 | 21 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,101 | 1,089 | 1,068 | 1,054 | 1,044 | 849 | 837 | 827 | 816 | 809 | 563 | 505 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -0 | 1 | 1 | 0 | 0 | 0 | 1 | -1 | -1 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -653 | -595 | -546 | -496 | -455 | -419 | -379 | -339 | -305 | -273 | -245 | -215 | ||||||
| Stockholders Equity | 448 | 493 | 522 | 559 | 589 | 430 | 459 | 489 | 510 | 535 | 319 | 290 | ||||||
| Liabilities And Stockholders Equity | 480 | 519 | 553 | 583 | 613 | 454 | 487 | 511 | 532 | 554 | 340 | 311 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | ||||||
| Common Stock Shares Issued | 108 | 107 | 106 | 106 | 105 | 95 | 95 | 94 | 94 | 93 | 70 | 63 | ||||||
| Shares Outstanding | 108 | 107 | 106 | 106 | 105 | 95 | 95 | 94 | 94 | 93 | 70 | 63 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialEdgewise Therapeutics, Inc. (EWTX) — SEC Financial Statements & Analysis
Edgewise Therapeutics, Inc. (EWTX) is a pharmaceutical preparations company, incorporated in DE. Edgewise Therapeutics, Inc. trades on Nasdaq as: EWTX. Edgewise Therapeutics, Inc. (EWTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Edgewise Therapeutics, Inc. carries a market cap of $4.37B, a P/E ratio of -22.18x, a P/B ratio of 9.76x, an enterprise value of $4.30B, and an EV/EBITDA multiple of -19.85x. On profitability, it posts a Return on Equity (ROE) of -38.03%, a Return on Assets (ROA) of -36.09%, and a Return on Invested Capital (ROIC) of -47.51%. Per share, it reports EPS of $-1.83, diluted EPS of $-1.83, free cash flow per share of $-1.48, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 30.87% year-over-year and EPS growth of 27.55% year-over-year. On the balance sheet, it maintains a current ratio of 16.24x, a quick ratio of 16.01x, working capital of $442.48M, a debt-to-equity ratio of 0.07x, a debt ratio of 0.07, free cash flow of $-158.83M (TTM), and net debt of $-72.32M. Figures sourced from SEC EDGAR.
- Market Cap
- $4.37B
- P/E TTM
- -22.18x
- EPS TTM
- $-1.83
- P/B TTM
- 9.76x
- ROE TTM
- -38.03%
- ROA TTM
- -36.09%
- Debt To Equity
- 0.07x
- Free Cash Flow TTM
- $-158.83M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Edgewise Therapeutics, Inc. in?
Edgewise Therapeutics, Inc. (EWTX) operates in the Pharmaceutical Preparations industry.
What exchange does EWTX trade on?
Edgewise Therapeutics, Inc. (EWTX) trades on the Nasdaq.
Where is Edgewise Therapeutics, Inc. incorporated?
Edgewise Therapeutics, Inc. is incorporated in DE.
When was Edgewise Therapeutics, Inc. (EWTX)'s most recent SEC filing?
Edgewise Therapeutics, Inc. (EWTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is EWTX's market cap?
Edgewise Therapeutics, Inc. (EWTX) has a market capitalization of $4.37B as of 2026-06-30.
What is EWTX's EPS (earnings per share)?
Edgewise Therapeutics, Inc. (EWTX)'s trailing twelve month EPS is $-1.83 as of 2026-06-30.
What is EWTX's ROE (return on equity)?
Edgewise Therapeutics, Inc. (EWTX)'s trailing twelve month Return on Equity (ROE) is -38.03% as of 2026-06-30.
What is EWTX's ROA (return on assets)?
Edgewise Therapeutics, Inc. (EWTX)'s trailing twelve month Return on Assets (ROA) is -36.09% as of 2026-06-30.
What is EWTX's ROIC (return on invested capital)?
Edgewise Therapeutics, Inc. (EWTX)'s trailing twelve month Return on Invested Capital (ROIC) is -47.51% as of 2026-06-30.
What is EWTX's EV/EBITDA?
Edgewise Therapeutics, Inc. (EWTX)'s trailing twelve month EV/EBITDA is -19.85x as of 2026-06-30.